| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer
1 company
Sooin Hwang last filed a Form 4 in February 2022, as Chief Business Officer at VINC. Sooin Hwang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 390,491 shares of VINC. Net of sales, the VINC filings show accumulation of 3,500 shares.
Sooin Hwang has 3 Form 4 filings on record from June 2021 to February 2022, all as Chief Business Officer at Vincerx Pharma (VINC), 2021–2022.
The 3 reported transactions were 2 open-market purchases and 1 option or other derivative award.
Counted by filing, the open-market trades come to 2 purchases worth about $36K and no sales.
The largest open-market purchase was 3,000 shares of VINC at an average $10.00 on December 23, 2021, about $30K.
Shares as reported in the last Form 4 for each company; the most recent is from February 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.